ZA963593B - IL-6 activity inhibitor - Google Patents

IL-6 activity inhibitor

Info

Publication number
ZA963593B
ZA963593B ZA963593A ZA963593A ZA963593B ZA 963593 B ZA963593 B ZA 963593B ZA 963593 A ZA963593 A ZA 963593A ZA 963593 A ZA963593 A ZA 963593A ZA 963593 B ZA963593 B ZA 963593B
Authority
ZA
South Africa
Prior art keywords
pct
nucleotide sequence
date nov
absent
sec
Prior art date
Application number
ZA963593A
Other languages
English (en)
Inventor
Serlupi-Crescenzi Ottaviano
Pezzotti Annarita
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of ZA963593B publication Critical patent/ZA963593B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA963593A 1995-05-11 1996-05-07 IL-6 activity inhibitor ZA963593B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/001778 WO1996035782A1 (en) 1995-05-11 1995-05-11 Il-6 activity inhibitor

Publications (1)

Publication Number Publication Date
ZA963593B true ZA963593B (en) 1996-11-25

Family

ID=8166014

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA963593A ZA963593B (en) 1995-05-11 1996-05-07 IL-6 activity inhibitor

Country Status (16)

Country Link
US (1) US6004813A (uk)
EP (1) EP0824588B1 (uk)
JP (1) JP4173539B2 (uk)
KR (1) KR100449677B1 (uk)
AT (1) ATE271128T1 (uk)
AU (1) AU715125B2 (uk)
CA (1) CA2220433C (uk)
DE (1) DE69533264T2 (uk)
DK (1) DK0824588T3 (uk)
ES (1) ES2220929T3 (uk)
IL (1) IL118158A (uk)
MX (1) MX9708663A (uk)
RU (1) RU2205874C2 (uk)
UA (1) UA63888C2 (uk)
WO (1) WO1996035782A1 (uk)
ZA (1) ZA963593B (uk)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2237114A1 (en) * 1995-11-07 1997-05-15 Kaneka Corporation Autoantigens
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP0972780A1 (en) * 1998-05-18 2000-01-19 Applied Research Systems ARS Holding N.V. Il-6 antagonist peptides
BR9913562A (pt) 1998-09-11 2001-05-22 Ajinomoto Kk Derivados de benzeno, inibidor de ativação de ap-1 e nf-capa b, inibidor de produção de citoquina inflamatória, inibidor de produção de metaloprotease matricial ou inibidor de aparecimento de fator de adesão de célula inflamatório, e, agente antiinflamatório, anti-reumático, imunossupressor, inibidor de metástase cancerosa, remédio para arterioesclerose e agente antiviral
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU7078200A (en) 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
EP1296714B1 (en) 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
AU2003216585A1 (en) * 2002-04-10 2003-10-20 Orchid Chemicals And Pharmaceuticals Limited Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
AU2005235811B2 (en) * 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
EP1858845A2 (en) * 2005-03-18 2007-11-28 Orchid Chemicals and Pharmaceuticals Limited Novel tyrosine derivatives
US20080267888A1 (en) * 2005-05-26 2008-10-30 Pandey Surendrakumar Satyanara Heterocyclic Derivatives
JP2008543968A (ja) * 2005-06-28 2008-12-04 オーキッド リサーチ ラボラトリーズ リミテッド 新規なピラゾロピリミジノン誘導体
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
PL1973884T3 (pl) * 2006-01-19 2017-05-31 Orchid Pharma Limited Nowe związki heterocykliczne
US7863446B2 (en) * 2006-01-19 2011-01-04 Orchid Research Laboratories Limited Heterocycles
WO2008110891A2 (en) * 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
US7943591B2 (en) * 2007-05-11 2011-05-17 Adynxx, Inc. Gene expression and pain
BRPI0912029A2 (pt) 2008-02-01 2020-06-30 Orchid Research Laboratories Limited novos heterociclos
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
BR112016016400A2 (pt) 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
RU2017108238A (ru) 2014-08-15 2018-09-17 Эйдинкс, Инк. Олигонуклеотиды-приманки для лечения боли

Also Published As

Publication number Publication date
DE69533264T2 (de) 2004-11-25
US6004813A (en) 1999-12-21
CA2220433C (en) 2010-02-16
DE69533264D1 (de) 2004-08-19
JPH11504816A (ja) 1999-05-11
EP0824588A1 (en) 1998-02-25
AU2526795A (en) 1996-11-29
UA63888C2 (en) 2004-02-16
ES2220929T3 (es) 2004-12-16
ATE271128T1 (de) 2004-07-15
IL118158A (en) 2004-07-25
WO1996035782A1 (en) 1996-11-14
EP0824588B1 (en) 2004-07-14
CA2220433A1 (en) 1996-11-14
JP4173539B2 (ja) 2008-10-29
DK0824588T3 (da) 2004-08-16
MX9708663A (es) 1998-02-28
KR100449677B1 (ko) 2004-11-20
RU2205874C2 (ru) 2003-06-10
KR19990014681A (ko) 1999-02-25
AU715125B2 (en) 2000-01-20
IL118158A0 (en) 1996-09-12
HK1016213A1 (en) 1999-10-29

Similar Documents

Publication Publication Date Title
IL118158A0 (en) IL-6 activity inhibitor
IL108769A0 (en) Spirocyclic piperidine derivatives
KR950702180A (ko) 류코트리엔 생합성 억제제로서의 치환된 아릴알키닐-및 헤테로아릴알키닐-N-하이드록시우레아(substituted arylalkynyl-and heteroarylalkyny-N-hydroxyurea inhibi tors of leukotriene biosynthesis)본 내용은 요부공개 건이므로 전문 내용을 수록하지 않았음
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
DE69326250D1 (de) Neuropeptide y antagoniste
FI932229A0 (fi) Azabicykliska bryggderivat
NO990667L (no) Depeptid-benzamidin som kinogenase-inhibitor
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
YU25399A (sh) 6-fenilpiridil-2-amino derivati korisni kao nos inhibitori
ATE172968T1 (de) Substituierte azadioxacycloalkene und ihre verwendung als fungizide
AU5454894A (en) Pyrazoles having CRF antagonist activity
AU4304196A (en) Novel sulfonamides
MY117948A (en) Nitride oxide synthase inhibitors.
ATE172963T1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
ATE423562T1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
UA35589C2 (uk) ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
AU4263696A (en) Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof
PL317349A1 (en) Organic compounds
DE69307895D1 (de) Therapeutische verwendung von phosphoryl-l-serin-n-acyl-sphingosin
HUT73231A (en) Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis
NO962261D0 (no) Hirudin-konjugater av hirudin og lipofile forbindelser
GB2262528B (en) Further improvements relating to the radiolabelling of proteins
DE69405760D1 (de) 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
ZA982808B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia